» Articles » PMID: 33568225

The Views of New Zealand General Practitioners and Patients on a Proposed Risk Assessment and Communication Tool: a Qualitative Study Using Normalisation Process Theory

Overview
Publisher Biomed Central
Specialty Health Services
Date 2021 Feb 11
PMID 33568225
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Communicating risks of medication harm and obtaining informed consent is difficult due to structural barriers, language and cultural practices, bias and a lack of resources appropriately tailored for the health literacy of most patients. A decision support tool was proposed to alert prescribers of risk and provide tailored information for patients to facilitate informed decision-making with patients and their whānau (family) around medication use. Patient and prescriber co-design was used to ensure the tool was designed to best meet the needs of end-users and avoid increasing health inequity. This paper describes the first stage of the co-design process.

Method: Normalisation Process Theory (NPT) was used to prospectively evaluate the tool. Semi-structured interviews were held with fifteen patients (five Māori, five Pasifika and five NZ European) and nine general practitioners (two Māori and seven European).

Results: Three themes were identified, which related to the three NPT concepts most relevant to developing the tool. Theme 1 (coherence: meaning and sense making by participants) explored participants' understanding of prescribing safety, medication harm and risk, which is based on experience. Patients want as much information as possible about their medications and risk, but doctors find it difficult to communicate that information. Theme 2 related to the NPT concept of cognitive participation (commitment and engagement by participants) explored what participants thought about a prescribing decision support tool. Participants were cautiously optimistic, but worried about potential harm arising from its use. They also identified requirements for the tool and features to avoid. Theme 3 describes the collective action required for successful implementation of the tool; namely, culturally safe and trustworthy doctor-patient relationships.

Conclusion: Patients and general practitioners provided different perspectives when prospectively evaluating the proposed risk assessment and communication tool. This co-design research identified important pre-requisites for the tool and features to avoid and novel ideas for the proposed tool. Overall participants supported the development of the proposed risk assessment and communication tool, but identified the important role that doctor-patient relationships would play to ensure successful implementation. The use of Māori and Pacific languages in the proposed tool may enhance engagement and understanding.

Citing Articles

Avoiding anti-inflammatories: a randomised controlled trial testing the effect of an eHealth information package on primary healthcare patient medication knowledge and behaviour in Aotearoa New Zealand.

Leitch S, Zeng J, Smith A, Stokes T BMJ Open. 2024; 14(11):e081545.

PMID: 39510789 PMC: 11552570. DOI: 10.1136/bmjopen-2023-081545.


Using an Information Package to Reduce Patients' Risk of Renal Damage: Protocol for a Randomized Feasibility Trial.

Leitch S, Smith A, Zeng J, Stokes T JMIR Res Protoc. 2021; 10(4):e29161.

PMID: 33929338 PMC: 8122288. DOI: 10.2196/29161.

References
1.
Berry D, Raynor D, Knapp P, Bersellini E . Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf. 2002; 26(1):1-11. DOI: 10.2165/00002018-200326010-00001. View

2.
Chin M, King P, Jones R, Jones B, Ameratunga S, Muramatsu N . Lessons for achieving health equity comparing Aotearoa/New Zealand and the United States. Health Policy. 2018; 122(8):837-853. PMC: 6561487. DOI: 10.1016/j.healthpol.2018.05.001. View

3.
Lawrenson R, Seneviratne S, Scott N, Peni T, Brown C, Campbell I . Breast cancer inequities between Māori and non-Māori women in Aotearoa/New Zealand. Eur J Cancer Care (Engl). 2016; 25(2):225-30. DOI: 10.1111/ecc.12473. View

4.
Paling J . Strategies to help patients understand risks. BMJ. 2003; 327(7417):745-8. PMC: 200818. DOI: 10.1136/bmj.327.7417.745. View

5.
Jatrana S, Crampton P, Norris P . Ethnic differences in access to prescription medication because of cost in New Zealand. J Epidemiol Community Health. 2010; 65(5):454-60. DOI: 10.1136/jech.2009.099101. View